Prescription Medicine

Oncology

Content filter:

All Lung Cancer Head&Neck Colorectal Cancer Oncology

Information for...

General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US Journalists Jobseekers

PRESS RELEASE 15 Nov 2018 at 12:30

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Read more on
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
PRESS RELEASE 19 Oct 2018 at 12:00

Real-world study shows using Giotrif^®/Gilotrif^® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC

Read more on
Real-world study shows using Giotrif^®/Gilotrif^® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
PRESS RELEASE 26 Sep 2018 at 10:00

Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

Read more on
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
PRESS RELEASE 25 Sep 2018 at 15:45

Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)

Read more on
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19^th World Conference on Lung Cancer (WCLC 2018)
PRESS RELEASE 13 Sep 2018 at 08:00

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Read more on
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
PRESS RELEASE 22 Jun 2018 at 14:00

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center

Read more on
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
PRESS RELEASE 25 Apr 2018 at 13:30

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Read more on
Boehringer Ingelheim R&D pushes to transcend disease boundaries
- Cancer Immunology Innovation Approach
PRESS RELEASE 04 Apr 2018 at 18:00

New Immuno-Oncology Partnership with OSE Immunotherapeutics to Develop a Pioneering Checkpoint Inhibitor

Read more on
New Immuno-Oncology Partnership with OSE Immunotherapeutics to Develop a Pioneering Checkpoint Inhibitor
PRESS RELEASE 13 Mar 2018 at 14:00

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Read more on
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
PRESS RELEASE 30 Oct 2017 at 14:00

Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy

Read more on
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
- Press_release_card_lung_cancer.jpg
PRESS RELEASE 09 Feb 2017 at 14:27

Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung

Read more on
Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung
- Press_release_card_lung_cancer.jpg
PRESS RELEASE 08 Nov 2016 at 09:30

New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients

Read more on
New European study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients
PRESS RELEASE 09 Oct 2016 at 08:15

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016

Read more on
Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016
PRESS RELEASE 09 Oct 2016 at 08:15

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016

Read more on
Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016
PRESS RELEASE 29 Sep 2016 at 14:00

Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies

Read more on
Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
- Electron micrograph of VSV-GP
PRESS RELEASE 28 Sep 2016 at 14:00

BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS

Read more on
BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS
- Laboratory equipment
PRESS RELEASE 01 Sep 2016 at 15:00

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE immuno-oncology drug for multiple myeloma

Read more on
Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE immuno-oncology drug for multiple myeloma
- R&D_017.jpg
PRESS RELEASE 14 Jul 2016 at 11:00

Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines

Read more on
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
- Breat_cancer_fotolia
PRESS RELEASE 13 Jul 2016 at 14:00

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

Read more on
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
PRESS RELEASE 30 Mar 2016 at 10:00

Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine

Read more on
Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine